2EyesVision key facts
as of Oct 2026- Developer of ophthalmic technologies designed to improve the clinical ophthalmology practice and make patients' lives easy.
- 2EyesVision is valued at approximately $17.1M as of Oct 2026 (last reported valuation).
- It has raised $11.4M; the latest was Equity Crowdfunding ($900K) in Oct 2025.
- Notable investors include INNVIERTE SICC, NextCorps Luminate, Bullnet Capital, EIT Health, Jan Bonel — 6 tracked in total.
- Status: Privately Held (backing).
2EyesVision's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch 2EyesVision: the Monday email on marks, rounds and moves
2EyesVision funding rounds
No funding rounds for 2EyesVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
2EyesVision valuation
2EyesVision's last reported valuation was $17.1 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
2EyesVision investors
6 investors are on record for 2EyesVision, including INNVIERTE SICC, NextCorps Luminate, Bullnet Capital and EIT Health.
About 2EyesVision
Developer of ophthalmic technologies designed to improve the clinical ophthalmology practice and make patients' lives easy. The company commercializes a visual simulator of presbyopic corrections for patients seeking refractive or cataract surgery to experience the real world before undergoing surgery, enabling opticians to recommend a noninvasive, personalized assessment before treatment.
- Sector
- Healthcare
- HQ
- Madrid, Spain
- Founded
- 2015
- Employees
- 14
- Website
- 2eyesvision.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.